Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodine hydrobromide injection for acute ischemic stroke
ChiCTR2100044939Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke and brain infarction comparing Anisodine hydrobromide + standard-of-care with Standard-of-care alone (2 arms). Primary endpoint: Proportion of patients with good functional outcome at 90 days. Started Apr 2021; status: recruiting.
02
Drugs
anisodine
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on ChiCTR2100044939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044939.